EXPERT LOGIN
The Cytonet Group is an international biotechnology company with locations in Weinheim and Heidelberg in Germany and in Durham, North Carolina in the U.S. The company develops, produces and markets cell therapeutic products, including human liver cells.  Cytonet’s goal is to  provide alternatives to existing therapies for many diseases with a particular emphasis on liver diseases.   Cytonet is a pioneer and leader in the field of regenerative medicine. Through the development of novel approaches to treatment we are helping to shape the future of medicine.


________________________________


  • Cytonet Recognizes Rare Disease Day with Efforts to Help Ensure - UCD Diagnoses Are Not Missed
    Heidelberg/Germany, February 27, 2012 – For parents of babies born with urea cycle disorders (UCD), the joy of giving birth to a perfect baby can quickly turn ...  read on

  • Cytonet Trials Aim to Better Assess Severity of Urea Cycle Disorders - Using New Assay for Urea Production
    Heidelberg/Germany, February 2012 – International biotechnology firm Cytonet has launched a new clinical trial in Germany to compare the urea cycle activity of pediatric  patients suffering from ...  read on

  • CYTONET SPONORS RIDER ON DONATE LIFE ROSE PARADE FLOAT
    Fort Worth/ Texas, November 2011 – Giant floral clocks will rise above 28 individuals whose participation as riders aboard Donate Life’s ninth Rose Parade Float will inspire ...  read on

  • American SELICA III trial to be extended into Canada
    Weinheim/ Germany, October 2011 –The Canadian health authority, Health Canada, recently granted Cytonet approval to extend the SELICA III trial, which has been open in the United ...  read on

  • HOME PRESS CONTACT MEDIA VIDEOS CONTACT LEGAL NOTICE